Skip to main content

Table 2 Factors associated with the prescription of second-line therapy (bivariate analysis)

From: Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Variable, Abiraterone plus prednisone
N = 100
Other 2nd line therapy
N = 50
p-value
Age, mean (SD) 73.5 (8.3) 69.6 (8.2) 0.008
ECOG*, n (%)
 0 21 (26.6) 9 (20.5) 0.329
 1 48 (60.8) 25 (56.8)
 2 9 (11.4) 10 (22.7)
 3 0 (0.0) 0 (0.0)
 4 1 (1.2) 0 (0.0)
Lifetime diabetes (yes), n (%) 17 (17.0) 9 (18.0) 0.879
Lifetime cardiovascular disorders (yes), n (%) 19 (19.0) 8 (16.0) 0.652
Lifetime hypertension (yes), n (%) 52 (52.0) 28 (56.0) 0.643
Disease symptoms and/or signs* (yes), n (%) 57 (60.0) 34 (70.8) 0.203
Anemia (yes), n (%) 16 (16.5) 15 (30) 0.062
LDH increased (yes), n (%) 45 (52.9) 35 (77.8) 0.006
Alkaline phosphatase increased (yes), n (%) 32 (34.4) 26 (55.3) 0.018
  1. ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; SD, standard deviation
  2. *Missing data: ECOG, abiraterone n = 21, other n = 6; Disease symptoms and/or signs, abiraterone n = 5, other n = 2; Anemia, abiraterone n = 3, other n = 0; LDH increased, abiraterone n = 15, other n = 5; Alkaline phosphatase increase, abiraterone n = 7, other n = 6 (3)
\